# Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)

> **NCT02640209** · EARLY_PHASE1 · TERMINATED · sponsor: **University of Pennsylvania** · enrollment: 20 (actual)

## Conditions studied

- LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)

## Interventions

- **BIOLOGICAL:** CART 19

## Key facts

- **NCT ID:** NCT02640209
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-01-29
- **Primary completion:** 2018-10-15
- **Final completion:** 2019-07-16
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Study is terminated due to administrative reasons.
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02640209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02640209, "Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02640209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*